department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

pharmaand GmbH · pharmadog

PUBLIC COMPANY

pharmaand GmbH

updated 1mo ago

community read0 votes

pipeline

3

marketed

2

phase 3

0

catalysts ytd

0

approvals ytd

0

recalls ytd

0

Pipeline(3)

pipeline depth3 products

2Marketed1Unknown

peginterferon alfa-2a

rucaparib camsylate

Epithelial Ovarian Cancer

PARP 1, 2 and 3

Upcoming

no upcoming catalysts on record

Recent(90d)

nothing in the last 90 days

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view pharmaand GmbH jobs →

News

no news has mentioned this company yet

identifiers

source

globaldata

top tags

Infectious Disease1 Oncology1

mentioned in

0news items

entity-linker matched

Data sources

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Active trials

phase3A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiencycompletedn=405
phase3A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapyactive not recruitingn=1,097
phase2Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myelomacompletedn=248
phase3CATCH-R: A Rollover Study to Provide Continued Access to Rucaparibcompletedn=34
phase2A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)terminatedn=25
phase2A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genesterminatedn=83
phase1Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)completedn=8
—A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostatcompletedn=248

more trials →

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?